Evaluation of motor response in mucopolysaccharidosis patients treated with enzyme replacement therapy

Ortopedia Traumatologia Rehabilitacja

Volumn 15, Issue 5, 2013, Pages 389-393

  Matos, Marcos Almeida ^a,b   Barreto, Rosa ^a,b   Acosta, Angelina Xavier ^a,b  

^a ESCOLA BAHIANA DE MEDICINA E SAÚDE PÚBLICA   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

Evaluation; Mucopolysaccharidosis; Musculoskeletal system; Treatment

Indexed keywords

CONVALESCENCE; DRUG EFFECTS; ENDURANCE; ENZYME REPLACEMENT; FEMALE; FOLLOW UP; HUMAN; JOINT CHARACTERISTICS AND FUNCTIONS; MALE; MOTOR ACTIVITY; MUCOPOLYSACCHARIDOSES; PHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME; WALKING;

ENZYME REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MOTOR ACTIVITY; MUCOPOLYSACCHARIDOSES; PHYSICAL ENDURANCE; RANGE OF MOTION, ARTICULAR; RECOVERY OF FUNCTION; TREATMENT OUTCOME; WALKING;

EID: 84892727774     PISSN: 15093492     EISSN: None     Source Type: Journal    
DOI: 10.5604/15093492.1084240     Document Type: Article

References (17)

1. Valayannopoulos V, Nicely H, Paul Harmatz P, Turbeville S. Mucopolysaccharidosis VI. Orphanet J Rare Dis 2010;5:5.
2. Neufeld EF, Muenzer J. The mucopolysaccharidosis. In: Scriver CR, Beandet AL, Sly S, Valle D, Childs B, Kinzler KW, Volgesltein B. The metabolic and molecular basis of inherited disease. New York: McGraw-Hill; 2001.
3. Pinto LLC, Schwartz IV, Puga AC, Vieira TA, Munoz MV, Giugliani R. Prospective study of 11 Brazilian patients with mucopolysaccharidosis II. J Pediatr (Rio J) 2006; 82(4): 273-278.
4. Giugliani R, Federhen A, Munoz MVR, Vieira TA, Artigalas O, Pinto LL et al. Enzyme replacement therapy for mucopolysac-charidoses I, II and VI: recommendations from a group of Brazilian F experts. Rev Assoc Med Bras 2010;56(3):271-277.
5. Simonaro CM, Ge Y, Eliyahu E, He X. Jepsen KJ, Schuchman EH. Involvement of the Toll-like receptor 4 pathway and use of TNF-α antagonists for treatment of the mucopolysaccharidosis. Proc Natl Acad Sci 2010;107(1):222-227.
6. Simonaro CM, D'Angelo M, He X, Eliyahu E, Shtraizent N, Haskins ME, Schuchman EH. Mechanism of Glycosaminoglycan-Mediated Bone and Joint Disease: Implications for the Mucopolysaccharidoses and Other Connective Tissue Diseases. Am J Pathol 2008;172(1):112-122.
7. Palisano R, Rosenbaum P, Walter S, Russel D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 1997;39:214-223.
8. Gajdosik RL, Bohannon RW. Clinical measurement of range of motion. Review of goniometry emphasizing reliability and validity. Phys Ther 1987;67:1867-1872.
9. Cipriano JJ, Jahn WT. Photographyg manual of regional orthopedic and neurological tests. 3th ed. New York: Williams & Wilkins; 1999.
10. Haddad FS, Jones DHA, Vellodi A, Kane N, Pitt MC. Carpal tunnel syndrome in the mucopolysaccharidoses and mucopolilipidoses. J Bone Joint Surg 1997;79-B:576-82.
11. Haskins, M. Gene Therapy for Lysosomal Storage Diseases (LSDs) in Large Animal Models. ILAR Journ 2009;50(2):112-121.
12. Sifuentes M, Doroshow R, Hoft R, Mason G, Walot I, Diament M, Okazaki S, Huff K, Cox GF, Swiedler SJ, Kakkis ED. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Gen Metab 2007; 90:171-180.
13. Tylki-Szymanska A, Marucha J, Jurecka A, Syczewska M, Czartoryska B. Efficacy of recombinant human alpha-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients. J Inherit Metab Dis 2010;33(2):151-157.
14. Clarke LA, Wraith JE, Beck M, Kolodny EH, Pastores GM, Muenzer J, Rapoport DM, Berger KI, Sidman M, Kakkis ED, Cox GF. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 2009; 123(1): 229-240.
15. Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, Izykowski B, Phillips J, Doroshow R, Walot I, Hoft R, Neufeld EF. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001;344(3):182-188.
16. Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N, Meldgaard Lund A, Malm G, Van der Ploeg AT, Zeman J. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 2008;167:267-277.
17. Cox-brinkman J, Smeulders MJ, Hollak CE, Wijburg FA. Restricted upper extremity range of motion in mucopolysaccharidosis type I: no response to one year of enzyme replacement therapy. J Inherit Metab Dis 2007;30(1):47-50.